Advertisement
BMY vs MRK
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. Merck & Co. (MRK) Stock Comparison
Key Takeaways
- BMY provides a higher dividend yield of approximately 4.3% compared to MRK's 3.1%, appealing to income-oriented investors.
- Both stocks have experienced downward pressure in recent weeks, with MRK declining more sharply over the past month (around 5-8%) than BMY (1-2%).
- MRK boasts a larger market capitalization (~$272 billion) and stronger year-to-date gains historically, though BMY leads YTD at +9.5% versus +5.5%.
- Upcoming Q1 earnings for both on April 30 could drive sentiment, with BMY facing expected revenue softness and MRK bolstered by Keytruda growth.
- MRK's recent acquisitions and approvals signal pipeline momentum, while BMY emphasizes dividend stability and partnerships.
Introduction
Bristol-Myers Squibb (BMY) and Merck & Co. (MRK) are pharmaceutical powerhouses dominating oncology and cardiovascular markets. This comparison analyzes their recent market positioning, performance, and catalysts amid sector headwinds like patent expirations and generic competition. Dividend-focused investors may eye BMY's yield, while growth seekers track MRK's blockbuster drugs. Traders benefit from understanding relative momentum ahead of earnings, helping navigate volatility in healthcare stocks.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY) specializes in oncology, immunology, and cardiovascular therapies, with key products like Opdivo (immuno-oncology) and Eliquis (blood thinner). Trading around $58 per share with a market cap of about $118 billion, the stock has shown resilience year-to-date (+9.5%) but softened 1-2% over recent weeks amid broader market caution. Influences include anticipation of Q1 earnings (expected EPS of $1.44, down 20%, on $10.92 billion revenue) and partnerships like discounted Eliquis via Cost Plus Drugs. A recent dividend hike to $0.63 quarterly (yield ~4.3%, price-to-earnings (PE) ratio ~16.7) supports sentiment, offsetting generic pressures on older drugs.
MRK Overview and Recent Performance
Merck & Co. (MRK) leads in oncology via Keytruda (PD-1 inhibitor) and vaccines, with a market cap near $272 billion. Shares hover around $110, down 5-8% in recent weeks and YTD at +5.5%, reflecting sector rotation and acquisition integration. Key drivers include antitrust clearance for its $6.7 billion Terns Pharmaceuticals buyout, European approval for Enflonsia (RSV vaccine), and Keytruda's sustained demand. Q1 earnings loom with projected $15.9 billion revenue; dividend yield stands at 3.1% (PE ~15.1), balancing growth with income.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top performers, curating just 25 bots from over 351 available AI trading bots that analyze thousands of tickers across various strategies. These bots employ diverse approaches—scalping, swing trading, long-term trends—with metrics like win rates often exceeding 60%, profit factors above 1.5, and average gains from 1-5% per trade, tailored to current volatility and sector rotations. Suitable for stocks like pharma names, they adapt to market conditions, offering backtested performances and real-time signals. Traders can explore these elite bots to enhance decision-making in dynamic environments like the ongoing healthcare pullback.
Head-to-Head Comparison
Both BMY and MRK anchor in oncology but diverge in scale: MRK's Keytruda drives higher growth (past-year ~35% vs. BMY's 20%), yet faces 2028 patent risks. BMY counters with diversified immunology and superior dividends, trading at a value premium amid Eliquis generics. Recent momentum favors BMY short-term stability, while MRK edges on catalysts like acquisitions. Risks include regulatory hurdles and M&A debt for both; sentiment tilts toward MRK for innovation exposure versus BMY's income reliability.
Tickeron AI Verdict
Tickeron’s AI currently favors MRK with moderate conviction, citing consistent Keytruda revenue, acquisition-driven pipeline expansion, and superior long-term relative performance despite recent dips. BMY appeals for value and yield, but MRK's catalysts position it better for trend recovery post-earnings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a StrongBuy and MRK is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 2 FA rating(s) are green whileMRK’s FA Score has 3 green FA rating(s).
- BMY’s FA Score: 2 green, 3 red.
- MRK’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 5 TA indicator(s) are bullish while MRK’s TA Score has 6 bullish TA indicator(s).
- BMY’s TA Score: 5 bullish, 4 bearish.
- MRK’s TA Score: 6 bullish, 4 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а +6.13% price change this week, while MRK (@Pharmaceuticals: Major) price change was +3.28% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.82%. For the same industry, the average monthly price growth was +14.53%, and the average quarterly price growth was +6.94%.
Reported Earning Dates
BMY is expected to report earnings on Jul 30, 2026.
MRK is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.82% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| BMY | MRK | BMY / MRK | |
| Capitalization | 119B | 320B | 37% |
| EBITDA | 15B | 19.4B | 77% |
| Gain YTD | 11.409 | 24.889 | 46% |
| P/E Ratio | 15.81 | 32.53 | 49% |
| Revenue | 48.5B | 65.8B | 74% |
| Total Cash | N/A | N/A | - |
| Total Debt | 46.4B | 49.1B | 95% |
BMY | MRK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 14 Undervalued | |
PROFIT vs RISK RATING 1..100 | 88 | 41 | |
SMR RATING 1..100 | 25 | 47 | |
PRICE GROWTH RATING 1..100 | 47 | 12 | |
P/E GROWTH RATING 1..100 | 62 | 6 | |
SEASONALITY SCORE 1..100 | 50 | 47 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMY's Valuation (3) in the Pharmaceuticals Major industry is in the same range as MRK (14). This means that BMY’s stock grew similarly to MRK’s over the last 12 months.
MRK's Profit vs Risk Rating (41) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (88). This means that MRK’s stock grew somewhat faster than BMY’s over the last 12 months.
BMY's SMR Rating (25) in the Pharmaceuticals Major industry is in the same range as MRK (47). This means that BMY’s stock grew similarly to MRK’s over the last 12 months.
MRK's Price Growth Rating (12) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (47). This means that MRK’s stock grew somewhat faster than BMY’s over the last 12 months.
MRK's P/E Growth Rating (6) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (62). This means that MRK’s stock grew somewhat faster than BMY’s over the last 12 months.
| BMY | MRK | |
|---|---|---|
| RSI ODDS (%) | 5 days ago 33% | 5 days ago 51% |
| Stochastic ODDS (%) | 5 days ago 58% | 5 days ago 63% |
| Momentum ODDS (%) | 5 days ago 48% | 5 days ago 56% |
| MACD ODDS (%) | 5 days ago 54% | 5 days ago 52% |
| TrendWeek ODDS (%) | 5 days ago 52% | 5 days ago 55% |
| TrendMonth ODDS (%) | 5 days ago 56% | 5 days ago 54% |
| Advances ODDS (%) | 8 days ago 53% | 8 days ago 54% |
| Declines ODDS (%) | 6 days ago 55% | 6 days ago 51% |
| BollingerBands ODDS (%) | 5 days ago 57% | 5 days ago 57% |
| Aroon ODDS (%) | 5 days ago 53% | 5 days ago 64% |
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
|---|---|---|---|---|
| BMY | 100% | +4.16% | ||
| PFE - BMY | 59% Loosely correlated | +1.84% | ||
| AMGN - BMY | 57% Loosely correlated | +3.55% | ||
| NVS - BMY | 55% Loosely correlated | +3.74% | ||
| ABBV - BMY | 53% Loosely correlated | +3.99% | ||
| GSK - BMY | 53% Loosely correlated | +4.60% | ||
More | ||||
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with GSK. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then GSK could also see price increases.